Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: nateglinide

« Back to Dashboard

Nateglinide is the generic ingredient in two branded drugs marketed by Dr Reddys Labs Ltd, Par Pharm, Teva Pharms, Watson Labs, and Novartis, and is included in five NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for nateglinide. One supplier is listed for this compound.

Summary for Generic Name: nateglinide

Tradenames:2
Patents:4
Applicants:5
NDAs:5
Drug Master File Entries: see list8
Suppliers: see list1
Therapeutic Class:Blood Glucose Regulators

Pharmacology for Ingredient: nateglinide

Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists

Clinical Trials for: nateglinide

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Status: Completed Condition: Diabetes Mellitus, Type 2

Study of the Durability of Glycemic Control With Nateglinide
Status: Recruiting Condition: Type 2 Diabetes Mellitus

Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
Status: Completed Condition: Diabetes Mellitus, Type 2

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fed Condition
Status: Completed Condition: Healthy

Bioequivalence Study of Nateglinide Tablets 120 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Status: Completed Condition: Healthy

Effects of Nateglinide on Postprandial Glucose Excursion by Restoring Early Phase Insulin Secretion
Status: Completed Condition: Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms
NATEGLINIDE
nateglinide
TABLET;ORAL077467Sep 9, 2009DISCNNo<disabled><disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXYes6,844,008<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXYes6,641,841<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXNo6,844,008<disabled>Y<disabled>
Novartis
STARLIX
nateglinide
TABLET;ORAL021204Dec 22, 2000RXYes6,559,188<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc